Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 362-370, September 2009

Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells

  • Stephanie Hehlgans

      Affiliations

    • OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
  • ,
  • Iris Eke

      Affiliations

    • OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
  • ,
  • Katja Storch

      Affiliations

    • OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
  • ,
  • Michael Haase

      Affiliations

    • Department Children’s Surgery, Dresden University of Technology, Dresden, Germany
    • Department of Pathology, Dresden University of Technology, Dresden, Germany
  • ,
  • Gustavo B. Baretton

      Affiliations

    • Department of Pathology, Dresden University of Technology, Dresden, Germany
  • ,
  • Nils Cordes

      Affiliations

    • OncoRay – Center for Radiation Research in Oncology, Dresden University of Technology, Dresden, Germany
    • Corresponding Author InformationCorresponding author. Address: OncoRay – Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74/PF 86, 01307 Dresden, Germany.

Received 22 April 2009; received in revised form 30 June 2009; accepted 3 July 2009. published online 10 August 2009.

Abstract 

Background and purpose

Resistance of pancreatic ductal adenocarcinoma (PDAC) to chemo- and radiotherapy is a major obstacle. The integral membrane protein Caveolin-1 (Cav-1) has been suggested as a potent target in human pancreatic carcinoma cells.

Materials and methods

Human pancreatic tumor cells were examined in a three-dimensional (3D) cell culture model with regard to clonogenic survival, apoptosis, radiogenic DNA-double strand breaks and protein expression and phosphorylation under siRNA-mediated knockdown of Cav-1 without and in combination with irradiation (X-rays, 0–6Gy). Immunohistochemistry was used to assess Cav-1 expression in biopsies from patients with PDAC.

Results

Tumor cells in PDAC showed significantly higher Cav-1 expression relative to tumor stroma. Cav-1 knockdown significantly reduced β1 integrin expression and Akt phosphorylation, induced Caspase 3- and Caspase 8-dependent apoptosis and enhanced the radiosensitivity of 3D cell cultures. While cell cycling and Cav-1 promoter activity remained stable, Cav-1 knockdown-induced radiosensitization correlated with elevated numbers of residual DNA-double strand breaks.

Conclusions

Our data strongly support the concept of Cav-1 as a potent target in pancreatic carcinoma cells due to radiosensitization and Cav-1 overexpression in tumor cells of PDAC. 3D cell cultures are powerful and useful tools for the testing of novel targeting strategies to optimize conventional radio- and chemotherapy regimes for PDAC.

Abbreviations: Cav-1, Caveolin-1, DNA-DSB, DNA-double strand break, ECM, extracellular matrix, FAK, focal adhesion kinase, GSK3β, glycogen synthase kinase-3β, ILK, integrin-linked kinase, IP, immunoprecipitation, lrECM, laminin-rich extracellular matrix, PINCH-1, particularly interesting new cysteine–histidine-rich protein 1, rDNA-DSB, residual DNA-double strand break

Keywords: Caveolin-1, β1 integrin, Ionizing radiation, Three-dimensional cell culture, Pancreatic carcinoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(09)00393-4

doi:10.1016/j.radonc.2009.07.004

Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 362-370, September 2009